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1INTRODUCTION
Acute coronary syndrome includes unstable angina and non-ST elevated
myocardial infarction and is defined as a spectrum of disease characterized by
either:
1. New onset angina.
2. Angina at rest
3. Progression of angina of increasing frequency or severity.
4. Angina in response to lower levels of exertion.
5. STEMI
Acute coronary syndrome most often represents acute atherosclerotic
plaque rupture with exposure of thrombogenic sub-endothelial matrix.
Coronary atheroma occurs as a result of inflammatory process. Cellular
inflammation and local inflammation in the arterial wall occurs as a result of
cytokines, which can further progress to cause vascular smooth muscle apoptosis,
degradation of the fibrin cap and plaque rupture.
Clinically patient can have unstable angina or progressed to myocardial
infarction as a consequence of thrombus formation due to platelet aggregation.
Cytokines have pivotal role in pathogenesis of atheroma formation. Pro-
inflammatory cytokines are suppressed by testosterone which shows immune-
modulating effect. Men with low testosterone levels are at increase risk of
developing acute coronary syndrome.
2An anti-inflammatory effect of normal physiological levels of sex
hormones may therefore, be important in atheroma protection. Cytokines and C-
reactive proteins are found to be elevated in coronary heart disease patients.
Low serum testosterone levels is found in patients with coronary heart
disease. Two most important activities in the pathogenesis of atheroma formation
are cytokine activation and vascular smooth muscle cell apoptosis.
 Main action of  testosterone hormone is to deactivate cytokines as a result
of which smooth muscle apoptosis is inhibited and leads to smooth muscle
proliferation. So, as a consequence of this smooth muscle proliferation action by
this hormone, it helps in maintaining the fibrous cap of the atherosclerotic plaque.
Testosterone hormone has calcium channel antagonism which results in
coronary artery vasodilation. Various studies have proved the beneficial effect of
testosterone hormone in coronary heart disease patients.
 The following study is done to show the association of serum testosterone
levels in patients with coronary heart disease.
3AIMS AND OBJECTIVES
? To estimate the level of free testosterone level in male patient suffering
acute coronary syndrome.
? To correlate free testosterone level with mortality and morbidity in male
patients presenting with acute coronary syndrome.
? To correlate free testosterone level in male patients of acute coronary
syndrome with other parameters e.g. BMI, lipid abnormality & ECG
changes.
4REVIEW OF LITERATURE
Atherosclerotic coronary artery disease (CAD) is a leading cause of
mortality and morbidity all over the world. Men are more than twice as likely to
develop CAD. Incidence of coronary heart disease in females when compared to
male is low before menopause but it is of same incidence after menopause.
TESTOSTERONE
Leydig cells of testis produces testosterone which is synthesized from
cholesterol and also from androstenidione secreted by the adrenal cortex. Leydig
cells which is present in testis is controlled by LH for the secretion of hormone
testosterone. Normal level of testosterone in adult – 4 to9ng/day secretion.
Testosterone bound to protein is 98% and only 2% is free. Out of that 985 bound
form65% is combined with beta globulin called gonadal steroid binding globulin
and 33% bound to albumin.
 Minimal quantity of testosterone is converted to estradiol but maximum
quantity is converted to 17-keto steroids (like androsterone and etiocholanolone)
and excreted in urine. About 70% of urinary 17-keto steroids are of adrenal origin
and 30% of testicular origin.
5Formula: C19H2802
Molecular mass: 288.42 g/mol
Melting point: 155 0 C
6SYNTHESIS
Leydig cell is being acted upon by LH to stimulate testosterone stimulation.
Feedback mechanism on hypothalamus and pituitary by testosterone and estrogen
regulates the androgen synthesis.
7SYNTHESIS OF TESTOSTERONE
LH + 7-transmembrane, G protein–coupled receptor
?
cyclic AMP pathway activated
?
8LH receptor stimulated
?
Steroid acute regulatory protein produced ( rate limiting step)
?
Helps delivery of cholesterol to inner mitochondrial membrane
?
Formation of pregnenolone by CYP11A1
?
Testosterone produced
                             Dihydro testosterone               estradiol
                                 (more potent)
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Testosterone has inverse relationship with visceral fat. Androgen receptors
are more in number in visceral fat, as a result, it inhibits the action of lipoprotein
lipase and fatty acid/triglyceride uptake. Thus limits the fat accumulation.
 As the age progresses, the level of testosterone decreases and this allows
increase in fat concentration. And also due to aromatization of testosterone to
estradiol in obese old age patients, there is a doubt whether hormonal therapy
reduces visceral obesity.
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TESTOSTERONE AND CORONARY ARTERY DISEASE (CAD)
Serum testosterone has negative correlation with the extent of coronary
heart disease which was proved by performing coronary angiogram. Patients who
had angina and exercise induced ST segment depression have been benefited from
testosterone therapy.
High androgen levels are presumed by many to explain the male
predisposition to coronary artery disease. However, natural androgens inhibit male
atherosclerosis.
As age advances, serum testosterone levels decrease with concurrent
gonadotropin release with increased FSH and LH.
The ratio of estradiol to testosterone is raised in elderly male, which
suggests that hyperestrogenemia may lead to M.I in men.
The ratio of male to female having CAD in old age group after menopause
in female is 2:1. Premenopausal women are protected from endogenous estrogens
while postmenopausal women are treated with exogenous estrogens. Replacement
of natural analogues inhibit atheroma formation in men.
Patients who are having adverse lipid profile, raised blood pressure,
obesity, insulin resistance and raised fibrinogen are found to have low testosterone
levels.
Patients who are having angina symptoms and ECG changes with ischemia
show improvement in testosterone therapy. Testosterone therapy has proved to
have coronary and systemic vasodilatation effect in animal models in vitro.
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Mortality in men is twice that of women who have protective effects of
endogenous and exogenous estrogen. The abuse of anabolic steroid which resulted
in sudden cardiac death leads the suggestion that it has delirious effects, but the
persons who are actually having high testosterone levels have beneficial effect on
cardiovascular system.
Studies have proved that intracoronary administration of testosterone have
shown to increase the coronary blood flow.
Menopausal equivalent is not present in males but hormone levels decrease
as the age advances, usually after the age of 30 years. Studies have proved that
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males of same age group, who are having CAD have low testosterone levels when
compared to men of same age group having normal coronary angiogram study.
Testosterone therapy delays the coronary event by their coronary
vasodilator property.
Major function of testosterone hormone is to preserve sexual function,
muscle tone, bone mineral density and post pubertal mood. Its level peaks during
morning hours and also in spring, showing circadian and circannual rhythm.
Testosterone is 68% bound to sex hormone binding globulin (SHBG),and 30% to
albumin and remaining 2% is free form, which is biologically active.
Serum testosterone level was found to be low in established CAD patient
compared to men of same age group having normal coronary angiogram.
Endogenous testosterone has direct relationship or correlation with HDL
level but has indirect or negative correlation with total cholesterol, LDL and
triglycerides.
Thus hypogonadal men have atherogenic dyslipidaemia whereas normal
men with low testosterone have adverse lipid profile.
High testosterone levels are associated with CAD and that low serum
testosterone is associated with increased aortic atheroma. Furthermore, low
testosterone levels are associated with several risk factors for the development of
CAD, including systemic hypertension, adverse lipid profile and high levels of
fibrinogen, insulin and procoagulable factors.
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Various studies shown that testosterone treatment leads to symptomatic
improvement in men with angina. The acute and chronic anti-ischemic properties
of testosterone mediated by coronary artery vasodilatation, which appears to
involve calcium channel antagonism in a gender- specific fashion.
The androgens possess immune-modulating properties and they suppress
the activity of pro-inflammatory cytokines while enhancing that of anti-
inflammatory factors. Thus hypogonadal men were found to have a greater degree
of inflammatory activation compared with healthy controls, including higher
serum cytokine levels. Androgen therapy in these patients led to a reduction in
circulating cytokines.
By the direct anti-inflammatory actions, testosterone also appears to have
an important effect on rates of vascular smooth muscle cell proliferation and
apoptosis which is an important factor in maintaining plaque integrity. The
anabolic actions of testosterone helps in increasing protein synthesis and skeletal
muscle cell size via nuclear transcription. Testosterone has been shown to inhibit
human neuronal apoptosis. Importantly, it has also been shown to enhance
proliferation of human vascular smooth muscle cells. Testosterone could,
therefore, potentially be involved in maintaining the fibrous cap of the
atherosclerotic plaque by promoting smooth muscle cell stability.
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Men with coronary artery disease had significantly lower levels of free
testosterone than did controls. The concentration of free testosterone diminished
with age, and a negative correlation was found between free testosterone and body
mass index. There is negative correlation between the concentration of free
testosterone and lipids. A low level of free testosterone may be related to the
development of coronary artery disease.
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CORONARY ARTERY DISEASE ; ACUTE CORONARY SYNDROME
Coronary artery disease (CAD) remains the number one cause of death in
developed countries, however, the largest projected increases in disease rates are
in developing countries. Angina pectoris is the principal manifestation of coronary
atherosclerosis. Patients with stable angina are at increased risk of atherosclerotic
plaque instability, the development of severe myocardial ischemia and the
development of acute events such as myocardial infarction (MI). In line with the
changing patterns of acute events, older descriptions such as sub endocardial and
Q-wave MI have now been replaced with the term acute coronary syndrome
(ACS). ACS include unstable angina (UA), non-ST segment elevation myocardial
infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI).
Epidemiology
Heart disease is predominantly a disease of the elderly. The first event
occurs at an average age of 65.8 years for men and 70.4 years for women. Some
50% of men and 63% of women who die suddenly from CHD have no previous
symptoms of the disease. In developing countries like India, the  incidence of
coronary artery disease has been rising steadily. In last three decades the
prevalence of coronary artery disease has increased two fold (from 2 to 4%) in
rural India and three fold (from 3.45 to 9.45%) in urban India. The prevalence is
higher in South India, 13% in urban areas and 7% in rural areas.
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ACS patients are divided into those without and those with ST-segment
elevation. The ACS without ST elevation include both UA and NSTEMI. UA is
further defined as ischemic pain at rest without elevation of biomarkers, whereas
NSTEMI requires increased serum biomarkers. STEMI has both ST-segment and
biomarker elevation. Using these criteria. MI (either NSTEMI or STEMI) is
defined as myocardial cell death due to prolonged ischemia irrespective of
electrocardiogram (ECG) changes. Myocardial necrosis can be confirmed by the
appearance of different proteins (biomarkers) released into the circulation by
damaged myocytes. These include myoglobin,  cardiac troponins T (TnT) and I
(TnI), creatine kinase  (CK-MB) and total creatine kinase (CK).
Acute Coronary Syndrome
No ST Elevation ST Elevation
Non ST Elevation MI
Unstable Angina Myocardial Infarction
    Non Q wave MI   Q wave MI
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Pathophysiology
UA, NSTEMI and STEMI are closely related conditions with similar
pathologies and clinical presentation, but with differing severity. They differ
primarily in whether the ischemia is severe enough to cause sufficient myocardial
damage to release detectable levels of indicators of myocardial injury, such as
troponins.
The pathophysiology of atherosclerosis and ACS is well characterized. The
earliest visible atherosclerotic lesion appears to be the fatty streak. Beginning in
early life, these fatty streaks, or Type II lesions, are slightly raised above the
intimal surface and predominantly contain foam cells derived from tissue
macrophages and T lymphocytes.
Fatty steaks may progress to become mature plaques. Platelets adhere to the
initial lesion and secrete growth factors including platelet-derived growth factor
(PDGF) that initiate smooth muscle cell migration from the media to the intima.
This is turn stimulates the production of collagen, elastin and glycoproteins, which
provide the connective tissue matrix of the plaque and give it structural strength.
The lesion then becomes covered by a fibromuscular cap consisting of
smooth muscle cells and collagen with a single layer of endothelial cells. This
whole entity is referred to as a raised fibrolipid or advanced plaque, and becomes
the substrate for plaque complications and the development of clinical symptoms.
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Plaque rupture
The rupture of an atherosclerotic plaque can initiate a range of
complications from UA and acute MI through to sudden cardiac death.
Acute coronary occlusion usually occurs through one of two distinct
processes. First, the endothelium covering the atherosclerotic plaque can become
denuded (endothelial erosion) with exposure of the prothrombotic sub
endothelium to the circulating blood. Second, plaque disruption may occur with
the tearing open of the fibrous cap (plaque rupture) to expose the highly
thrombogenic lipid core.
The type of thrombus (platelet plug or platelet-fibrin thrombus) and the
extent and duration of obstruction to coronary blood flow determine the effect on
the myocardium with the development of UA, NSTEMI, or STEMI.
Plaque rupture depends more on the type of plaque than its size. Major
determinants of plaque vulnerability include both local and systemic factors. Local
factors include size and consistency of the atheromatous core, thickness of the
fibrous cap, ongoing inflammation and repair with the cap, eccentric, plaque
shape, and shear forces.
Systemic factors promoting plaque rupture include physical triggers (e.g.
exertion in normally sedentary individuals), and high levels of psychological stress
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with attendant increased adrenergic tone, shear forces, and generalized
inflammation. The milieu of the plaque is also fundamental to its vulnerability.
Inflammation
Atherosclerosis is clearly an inflammatory disease and does not result
simply from the accumulation of lipids. Low grade coronary inflammation is
widespread throughout the coronary tree.
CRP, an acute phase reactant produced in the liver in response to
interleukin-6 (I1-6), is both a marker and mediator of vascular inflammation as
well as being a predictor of coronary events in patents with stable and unstable
angina.
The most useful way of CRP testing in the emergency room setting will be
among those with chest pain syndromes who have negative troponin levels.
Platelets and the coagulation system
Platelet activation is an essential step in the formation of platelet-rich
thrombi. The GP IIb/IIIa receptor is responsible for platelet aggregation and is
regarded as the final common pathway for platelet-platelet interaction.
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Diagnosis of ACS
All chest pain patients should have a resting 12-lead ECG. Patients with
chest pain can be categorized into those with
- Non-cardiac chest pain
- Stable angina
- UA
- NSTEMI or STEMI
Diagnosis is initially based on:
1. Clinical signs and symptoms
2. Resting 12-lead ECG
3. Cardiac enzymes/biomarkers.
Clinical history is important for both the diagnosis and risk stratification of
patients with ACS. Age, traditional CAD risk factors, use of aspirin, and
frequency of rest chest pain episodes are independent risks for adverse outcome.
Electrocardiography
A resting ECG should be obtained in all patients who present with chest
pain. While the ECG is normal in about one third of chest pain patients, the pattern
of ST and T wave abnormalities defines ACS patients as UA/NSTEMI versus
STEMI. Severe ischemia from UA/NSTEMI may be associated with transient ST
elevation, whereas the ST elevation in STEMI persists for hours. In some cases of
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UA and NSTEMI the ST segments are normal, even during pain, with
development of T wave inversion a few hours later. ECG findings further
determine risk in ACS. In-hospital death has been reported as 8.7% with non-
specific ECG changes and 11.5% with diagnostic results. Even a normal ECG
carries a 5.7% 7-day mortality.
New or reversible ST-segment deviation of 0.5 mm from baseline or left
bundle branch block on the admission ECG is associated with an increase in
incidence of death or MI at 1 year, i.e. 15.8% versus 8.2% in patients without ECG
changes. Reversible ST-segment depression is associated with a 3 to 6 fold
increase in death, MI, ischemia at rest, or provocable ischemia on exercise. The
ECG result and the CK level on admission can identify a difference in mortality
(in the group with ST-segment elevation plus depression and elevated CK level.
Cardiac enzymes and biomarkers
Standard blood testing for the patient with suspected ACS includes TnI or
TnT, total CK and CK-MB fraction. Elevated serum MB is an early marker of MI
with detection as early as an hour after onset of myocardial injury.
Cardiac isoforms of TnT and TnI are more specific and sensitive indicators
of myocardial damage and can detect the micro-infarctions typified by NSTEMI.
There appears little to choose between cTnT and cTnI. Studies of TnT
versus TnI indicate that the two markers are equally sensitive and specific, and
have similar prognostic significance.
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TIMI Risk Score
       -    Age > 65
- > 3 traditional risk factors for CAD (male sex, hyeprlipidemia,
hypertension, smoking, diabetes mellitus, family history of premature
CAD).
- Prior coronary stenosis > 50%.
- ST segment elevation or depression at presentation
- > 2 anginal events in the prior 24 hours
- Aspirin use in the prior 7 days
- Elevated serum cardiac biomarkers.
TIMI risk score can be used to define high risk (> 5 points), intermediate
risk (3-4 points), and low risk (0-2 points). The TIMI risk score is a validated way
to assess risk of cardiac events.
Inflammatory and other prognostic markers
Inflammation has been recognized as an important feature of the
pathophysiology of ACS. CRP is a strong independent marker of increased
cardiovascular risk in ACS. hsCRP is also an independent predictor of risk of MI,
stroke, peripheral vascular disease and sudden cardiac death even in apparently
healthy individuals. Both BNP and NT-pro BNP are elevated in ACS and both are
independent risk predictors of mortality.
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Exercise testing
Testing should be performed in most cases within 72 hours of presentation
in low or intermediate risk individuals who are free of active ischemia or heart
failure symptoms for a minimum of 8-12 hours, and in intermediate risk patients
after 2-3 days.
DANAMI-2 describes the prognostic importance of a pre-discharge
maximal exercise test following acute MI in the era of aggressive reperfusion
treatment – thrombolysis and percutaneous coronary intervention (PCI).
Echocardiography
Resting and stress echo play  role in the general assessment of CAD as
ischemia results in immediate changes that can be detected by echo. These
include:
? Abnormalities of wall motion – hypokinetic, akinetic, dyskinetic :
? Abnormalities of wall thickening – reduced or absent systolic thickening
or systolic thinning.
? Abnormalities of overall left ventricular function – e.g. ejection fraction.
Echocardiography can identify severe hypokinesis or akinesis of an
infracted area, which may be helpful in patients with a non-diagnostic ECG.
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Coronary angiography
Coronary angiography is regarded as the “gold standard” to define coronary
anatomy. Coronary angiography should be performed in patients where the
diagnosis cannot be reliably made using non-invasive testing. Patients with high-
risk clinical markers, who tend to be older, have multiple risk factors and have
previous MI, should undergo early coronary angiography. High-risk UA patients
who are refractory to medical therapy should be referred urgently for angiography.
Management of UA/NSTEMI
General treatment guidelines
The use of combination evidence-based medical treatments including
antiplatelet agents, beta-blockers, statins and ACE inhibitors has been shown to be
independently and strongly associated with lower 6- month mortality in patients
with ACS.
Anti-ischemic therapies
Nitrates: Their main role is to provide relief of pain. They act by arterial
vasodilatation, reduced myocardial oxygen demand, reduction in coronary
vasospasm, inhibition of platelet aggregation and augmentation of collateral blood
flow. There is no convincing evidence that nitrates reduce rates of death or re-
infarction.
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Nicorandil: It is a compound with potassium-channel opener and a nitrate moiety.
The IONA study showed that nicorandil 20 mg twice daily, in addition to
standard anti anginal therapy, improved outcomes in terms of reducing events
related to acute coronary disease and the associated requirement for admission to
hospital.
Beta-blockers
Patients with ACS with ST-segment elevation, who do not have
contraindications, should be treated with beta-blockers as soon as possible to
prevent acute MI/re-infarction. Similarly, oral beta-blockers are recommended for
long-term use, indefinitely, in all patients who recover from an acute MI.
Beta-blockers reduce the odds of death in long-term trials by 23% and in
short term trials by 4% following acute MI. These agents were associated with a
40% improvement in survival at 2 years, and suggested that the specific beta-
blocker chosen will have little influence on mortality.
Calcium antagonists
The anti anginal effects of calcium antagonists appear to be mediated
through a reduction of myocardial oxygen demand secondary to decreased
afterload and myocardial contractility.
Calcium antagonists may retard the atherosclerotic process.
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Oral antiplatelet therapies
Aspirin
Acute treatment with aspirin is recommended in all patients with suspected
ACS in the absence of contraindications. Aspirin should be administered as soon
as possible after patient presentation of suspected ACS and continued indefinitely.
Analysis of aspirin dose in the CURE study showed that medium-dose
(101-199 mg/day) and high-dose (> 200 mg/day) aspirin had no advantage over
low-dose (< 100 mg/day) aspirin whether patients received combination therapy
with clopidogrel or aspirin alone.
Clopidogrel
The CURE trial compared the benefit of aspirin plus clopidogrel (300 mg
loading dose, then 75 mg/day) treatment versus aspirin alone in 12,652 patients
with UA or NSTEMI treated for 3-12 months.
Clopidogrel was of benefit in the CURE trial irrespective of whether high-
risk features were present.
Intravenous antiplatelet therapies
GP IIb/IIIa receptor inhibitors
Several large randomized clinical trials have demonstrated improved
clinical outcomes associated with the administration of GP IIb/IIIa receptor among
patients presenting with ACS and after PCI.
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Antithrombin therapy
Unfractionated heparin
UFH reduces thrombin generation and Xa activity. This underlies the
rationale for its use in ACS.
Clinical experience
In UA, i/v UFH significantly reduced the risk of MI and recurrent
refractory angina by 89% and 63% respectively.
Recommendations and dosing
A weight-based UFH regimen is preferable, with a bolus of 60 to 70 U/kg
(maximum 5000 U) followed by an infusion of 12 to 15 U/kg/hour (maximum
1000 U) for 2 to 5 days.
Low molecular weight heparins
Enoxaparin is accepted as an anticoagulant in UA/NSTEMI.
Direct thrombin inhibitors
Hirudin can be used as an alternative to heparin among patients with HIT in
UA/NSTEMI.
PCI ad CABG
Both FRISC-II and TACTICS-TIMI-18 demonstrated significant reduction
of death, recurrent MI and hospitalization using the invasive approach. Early
invasive management of UA/NSTEMI for patients with moderate to high risk.
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Management of STEMI
Medical therapy
Nitrates
Oxygen
Analgesics
Morphine sulfate is the preferred analgesic agent to treat ongoing chest pain.
Antiplatelet agents
Patients should have immediate administration of non-enteric aspirin (162
mg or greater). Clopidogrel can be considered as an alternative antiplatelet agent
for  aspirin-sensitive patients. A 600 mg loading dose of clopidogrel may be
superior. Clopidogrel enhances reperfusion with thrombolysis. Dual antiplatelet
therapy reduced the composite endpoint of coronary artery occlusion, death or
recurrent MI from 21.7% to 15.0%.
Infarct size limitation
- Beta-blockers
-  Renin-angiotensin-aldosterone inhibition
Patients with a large anterior MI or left ventricular failure should be
considered for early treatment (within first 24 hours) with an oral ACE inhibitor.
- Statin
Intensive statin therapy is effective in secondary prevention for patients
presenting with ACS.
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Reperfusion options for treatment of STEMI
Reperfusion: fibrinolytic agents
Fibrinolytic drug administration
Drug Dosing Features
Streptokinase 1.5 million units over 30-60
minutes
Lower reperfusionr ate than
fibrin-specific agents,
lowest cost
Alteplase 15 mg bolus
- then 0.75 mg/kg over 30
minutes (maximum 50 mg)
- then 0.50 mg/kg over 60
minutes (maximum 35 mg)
Lower mortality than
streptokinase
Short half-life requires
infusion adjustment
Tenecteplase Weight-based single bolus
over 10 seconds
< 60 kg = 30 mg
60-69 kg = 35 mg
70-79 kg = 40 mg
80-89 kg = 45 mg
> 90kg = 50 mg
Efficacy similar to alteplase
with lower bleeding
complications when weight
adjusted.
Reteplase 10 units over 2 minutes
- then repeat 10 units at 30
minutes
Efficacy similar to alteplase
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Adjunctive therapies
Antiplatelet therapy
Heparin therapy
GP IIb/IIIa inhibitors
Elective PCI after fibrinolysis
Primary PCI
Newer agents like Ranolazine
Prognosis
30% of acute MI patients and 20% with UA experience a major event
(death or non-fatal coronary syndrome) during the first year after hospital
admission. Some 66% of all major events during the first 6 months post-MI occur
in the first 30 days. For hospitalized patients survival is determined importantly by
advanced age and presence of ventricular dysfunction, with residual myocardial
ischemia and cardiac arrhythmias contributing significantly. These complications
highlight the importance of an aggressive early treatment strategy for
UA/NSTEMI similar to STEMI patients.
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MATERIALS AND METHODS
Source:
For the study, male subjects presenting with acute coronary syndrome and
those patients who have recovered from a recent acute coronary event attending
Medicine OPD  were taken as cases. Age & sex matched healthy control were
taken from the medical ward. Study was done between October 2012 and
November 2013.
Number of cases - 50
Number of controls – 25
Inclusion criteria:
All male patients presenting with acute coronary syndrome between the age
group of 35-74 years.
Exclusion criteria:
? Patient with liver disease
? Patient with renal parenchymal disease
? Patient with diabetes mellitus
50 male patients with acute coronary syndrome were studied based on the
history, ECG changes, estimation of serum free testosterone and estimation of
cardiac markers wherever required.
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(a) History of angina:
Onset, situation, radiation, duration, aggravating and relieving factors were
studied.
(b) ECG changes:
? Resting ECG were obtained in all patients.
? ECG  studied for ST deviation, new onset left bundle branch block and
significant Q waves.
?
(c) Method of serum free testosterone study:
? 50 male subjects with defined acute coronary syndrome were studied and
serum free testosterone level were measured. Level of serum free
testosterone was estimated by chemiluminescence Radio immuno-assay
method.
Method of study
? Informed consent were obtained from all patients.
? Each patient was subjected to a detailed history and clinical examination.
Clinical examination include blood pressure measurement, general physical
examination, anthropometric measurement, body mass index and systemic
examination.
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? Biochemical parameter included fasting and random blood sugar, blood
urea, serum creatinine and lipid profile.
? History of hypertension, diabetes mellitus, chronic kidney disease and
dyslipidemia were noted.
? Presence of hypertension defined as per the Joint National Committee
(JNC) 7 criteria.
? Presence of diabetes mellitus defined by American Diabetes Association
Criteria.
? Presence of chronic kidney disease  defined by National Kidney Foundation
Criteria.
? Dyslipidemia as per ATP III guidelines.
? BMI  calculated as per latest WHO guidelines.
Statistical analysis:
In the present study, values are expressed as mean±2SD. Variables are
compared by  't' test for 2 sample mean. Attributes are compared by odds ratio and
standard error of difference between two proportions by Chi-square test.
p values < 0.05 were considered significant.
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OBSERVATION
In this study, 50 patients who presented with acute coronary syndrome were
studied, along with 25 age and sex matched controls, who did not have any
evidence of coronary artery disease.
Table - 1
Distribution of patients according to age
Age Cases Controls
35-44 12 10
45-54 14 11
55-64 15 4
65-74 9 0
Total 50 25
Majority of the case belonged to age group 55-64 (n=15). Mean age of the
cases was 53.36 yrs.
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Table - 2
Incidence of Different symptoms (n=50)
Symptoms No. of cases Percentage
Chest Pain 45 90%
Breathlessness 4 8%
Palpitation 28 56%
Syncope 3 6%
In the case group, most common presenting symptoms was chest pain
(n=45) in 90%, followed by palpitation (n=28) in 56% breathlessness and syncope
were found in 8% and 6% respectively.
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Table - 3
Distribution of risk factor in cases (n=50) & controls (n=25)
Risk Factor Cases Controls
Hypertension 17 7
Dyslipidemia 20 4
Smoking 23 5
Alcohol 2 2
Family History 3 2
 (a) Dysplipidemia is defined by any or all of the below:
T. cholesterol > 240 mg/dl
HDL-C < 40 or > 60 mg/dl
LDL-C > 130 mg/dl
Triglycerides > 160 mg/dl
Dyslipidemia was seen in 20 cases and 4 control patients.
(b) In case group (n=50), 17 patients had history of hypertension (34%) whereas in
control group 7 patients had hypertension (28%)
(c) In case group, 23 (46%) were chronic smokers, and among controls groups,
5(20%) were chronic smokers.
(d) In case group, 3(6%) had family history of coronary artery disease and in
control group 2(8%) had family history
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Table - 4
BMI in Cases & controls
BMI Cases Controls
18.5-24.9 37 25
25-29.9 13 0
>30 0 0
In the case group 13 patients (26%) were over weight. In the case group, 37
patients (74%) had normal BMI while 25 patients (100%) had normal BMI in
control group.
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Table - 5
Mean BMI in cases and controls
Cases Controls p value
23.40±2.35 20.64±1.52 < 0.05
(p value = 0.000001)
BMI in cases were higher than control group and the difference was
statistically highly significant.
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Table - 6
Mean BP in cases and controls
BP Cases (mmHg) Controls
(mmHg)
p value
SBP 129.36±24.79 118.8±9.27 p < 0.05
(p value = 0.04)
DBP 82.2±15.02 74.4±5.83 p < 0.05
(p value = 0.014)
Mean SBP and mean DBP were higher in cases than in controls and the
difference was statistically significant.
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Table - 7
Total cholesterol in case and controls
Total cholesterol (mg/dl) Cases Controls
< 200 19 20
201-239 8 1
> 240 23 4
In the case group, 23 patients (46%) had high levels of total cholesterol.
In the control, 4 patients (16%) had high total cholesterol.
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Table - 8
Mean total cholesterol (mg/dl) in cases and controls
Cases Controls p value
221.4±50.10 190.2±34.05 < 0.05
(p value = 0.006)
Mean total cholesterol level was higher in cases than in control group and
the difference was statistically significant.
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Table - 9
HDL-C level in cases and controls
HDL-C (mg/dl) Cases Controls
< 40 18 4
40-60 32 21
> 60 0 0
In the case group, 18 patients (36%) had HDL-cholesterol (HDL-C) level
less than 40 mg/dl and 32 (64%) had in the normal range, whereas in control
group, 4 (16%) had less than 40 mg/dl and 21 (84%) subjects had in the normal
range.
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Table - 10
Mean HDL-C (mg/dl) in cases and controls
Cases Controls p value
40.34±9.91 45.16±5.96 < 0.05
(p value = 0.02)
Mean total cholesterol level was less than control group and the difference
was statistically significant.
53
Table - 11
LDL-cholesterol level in cases and controls
HDL-C (mg/dl) Cases Controls
< 100 7 19
100-129 26 6
130-159 12 0
160-189 5 0
> 190 0 0
In the case group, 7 (14%) had LDL-C levels in optimal range while 19
(76%) in the control group had LDL-C levels in optimal range. 26 (52%) and 6
(24%) respectively in case and control groups had LDL-C levels in high normal
range. In case group, 5 patients (10%) had high LDL-C levels while none in
control group had high LDL-C level.
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Table - 12
Mean LDL-C (mg/dl) in cases sand control
Cases Controls p value
124.14±26.0 74.94±26.39 < 0.05
(p value = 0.0001)
In the case group, LDL-C was higher than the control group and the
difference was statistically significant.
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Table - 13
TG level in cases and controls
HDL-C (mg/dl) Cases Controls
< 160 42 21
> 160 8 4
In the case group 42 (84%) had TG levels in normal range and 8 (16%)
above normal.
In the control group, apparently 21(84%) had TG level in normal range.
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Table - 14
Mean TG (mg/dl) level in cases and controls
Cases Controls p value
136.9±34.8 101.2±33.07 < 0.05
(p value = 0.00006)
The difference in TG level in case and control group was statistically
significant.
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Table - 15
Serum free testosterone level and coronary artery disease (ACS) cross
tabulation
S. free testosterone Cases (ACS) Controls (without ACS)
< 9 ng/dl 40 1
> 9 ng/dl 10 24
Yates corrected Chi-square test : 35.84
Risk ratio (95% CI) : 3.32
Odds ratio (75% CI) : 96.00
p value = 0.000001 significant
In the present study group, the normal level  of serum free testosterone was
9-30 ng/dl.
In the case group, 40 patients (80%) had serum free testosterone level lesser
than 9 ng/dl while in control group only 1 subjects had lesser than 9 ng/dl. Serum
free testosterone level was significantly decreased in patients who had acute
coronary syndrome.
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Table - 16
Mean serum free testosterone level (ng/dl) in cases and controls
Cases Controls p value
8.36±1.80 12.94±3.06 < 0.05
(p value = 0.000001)
Mean serum free testosterone level was significantly decreased in the cases
than the controls and the difference was statistically significant.
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Table - 17
Mean serum free testosterone level (ng/dl) cross tabulation according to
number of cardiovascular risk factors in cases (n=50)
Cases with 0-2
risk factors
Cases with > 3 risk
factors
p value
Mean serum free
testosterone
8.02±1.23 8.58±2.08 0.33
Mean serum free testosterone level with cardiovascular risk factor did not
show statistically significant difference in the present study.
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Table - 18
Mean serum free testosterone (ng/dl) in hypertensive cases and hypertensive
controls
Cases Controls p value
8.38±1.56 11.27±1.85 < 0.05
(p value = 0. 0001)
Mean serum free testosterone in hypertensive cases was found to be lesser
than in hypertensive control and the study was statistically significant.
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Table - 19
Mean serum free testosterone level (ng/dl) in smokers (cases and controls)
Cases Controls p value
8.72±1.96 11.1±2.21 < 0.05
(p value = 0. 00001)
Mean serum free testosterone in smokers cases was found to be lesser than
in smoker control and the study was statistically significant.
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Table No. 20
Correlation of mean serum free testosterone level with pattern of ACS
ACS Cases Mean serum free
testosterone (ng/dl)
Percentage
AWMI 24 8.67±2.16 48%
IWMI 16 8.24±1.37 32%
UA 7 8.03±1.30 14%
AWMI+IWMI 3 7.31±1.83 6%
In the present study, most patients presented with AWMI (48%) followed
by IWMI (32%).
The mean serum free testosterone level in AWMI and IWMI were
8.67±2.16 ng/dl and 8.24±1.37 ng/dl respectively.
The mean serum free testosterone level was lowest (7.31±1.83 ng/dl) in
patients presented with  both AWMI and IWMI.
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Table No. 21
Correlation of mean serum free testosterone with mortality in acute coronary
syndrome
No. of cases Mean Serum free
testosterone (ng/dl)
Percentage
Mortality 2 10.1±4.6 4%
Survivors 48 8.28±1.66 96%
In the present study, most of the patient (96%) survived the attack while 2
patients (4%) succumbed to the illness. The mean serum free testosterone in
survivors and death were 8.28±1.66 ng/dl and 10.1±4.6 ng/dl respectively . There
was no correlation found between the serum free testosterone and mortality in
patients with acute coronary syndrome.
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DISCUSSION
Coronary artery disease (CAD) is a major cause of mortality and morbidity
in developed world, and in developing countries, the incidence is rising.
Atherosclerosis is the major cause of CAD. CAD manifests as acute coronary
syndrome (ACS) and stable angina.
Men are more than twice as likely as women to die from coronary heart
disease, and this ratio is consistent in all population and is not related to
differences in risk factors. Low testosterone level are associated with CAD  and
low serum testosterone is associated with increased aortic atheroma.
Furthermore, low testosterone levels are associated with several risk factors
for the development of  CAD including systolic and diastolic hypertension,
adverse lipid profile, and high levels of fibrinogen and procoagulable factors.
The present study is undertaken in order to correlate the role of serum free
testosterone in patients with ACS.
Age
The mean age was 53.36±10.57 yrs in the present study group. Majority of
the cases were in the age groups of 55-64 yrs (30%).
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Clinical presentation
In the present study, most common presenting symptoms was chest pain
(90%) followed by palpitation (56%).
Hypertension
In the present study, 34% patients had hypertension while only 28% of
controls had hypertension.
The mean systolic blood pressure (SBP) in cases was 129.36±24.79 mmHg
and mean diastolic blood pressure (DBP) was 82.2±15.02 mmHg.
Various other studies have shown the following parameters:
In 1994, the mean SBP was 134±22 mmHg and mean DBP was 74±14 mmHg.
In 2000 study, hypertension was found in 40.5% of cases.
In 2003 study, hypertension was found in 21.5% of cases.
In 2007 study, hypertension was found in 43.4% of cases.
The mean SBP was comparable to that seen in 2000 study was 131±7 mmHg.
The mean DBP was higher in our study group as compared to 1994 study
(74±14 mmHg) and  2000 study (78±2 mmHg).
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Smoking status
In the present study, 46% of cases and 20% of control were smokers.
In 2003 study, the incidence of smoking was 19%.
In 2007 study, the incidence of smoking was 37.2%.
Smoking incidence was comparatively higher in our study group, and is in
accordance with community trends.
Body Mass Index (BMI)
The mean BMI in the present study was 23.40±2.35 in cases and
20.64±1.52 in controls.
The mean BMI in 2007 study was 26.2±3.1 which is higher compared to
our study. The mean BMI in 2003 study was 25.5±3 and comparable to our study.
The mean BMI in 2000 study was 27.7±0.7.
In 2003 study, there was a negative correlation between free testosterone and body
mass index.
In 2005 study, it was found that the testosterone levels showed highly significant
negative correlation with BMI (p value < 0.001).
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Lipid profile
In the present study, the mean total cholesterol in cases was 221.4±50.10
mg/dl and in controls 190.2±34.05 mg/dl. The total cholesterol was higher in cases
than controls and the difference was statistically significant.
In 2007 study, total cholesterol was 247±25 mg/dl.
In 2003 study, total cholesterol was 226.6±1.11 mg/dl and is comparable to
our study.
The result of the present study and previous studies in accordance with
cardiovascular risk attributed to total cholesterol.
HDL CHOLESTEROL:
The mean HDL cholesterol level in cases was 40.34±9.91 mg/dl and control
was 45.16±5.96 mg/dl.
The mean HDL-C level in 2003 study was 51.81±0.33 mg/dl.
The mean HDL-C level in 2007 study was 47.95±0.32 mg/dl.
The lower level of HDL-C in case and control in our study is in accordance
to the prevalent lipid status of South Asian population.
LDL CHOLESTEROL:
The mean LDL-cholesterol level in the present study was 124.14±26 mg/dl
in cases and 74.94±26.39 mg/dl in controls, and the difference was statistically
significant.
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In 2007 study, the mean LDL-C level in case was 156±23 mg/dl.
In 2003 study, the mean LDL-C level was 150.42±0.98 mg/dl.
TRIGLYCERIDES:
The mean triglyceride level in the present case was 136.9±34.8 mg/dl.
The mean TG level in 2000 study was 76.95±1.09 mg/dl.
In 2003 study, the mean TG level in cases was 52.97±0.75 mg/dl.
The mean TG level in the present study was comparatively higher.
Serum free testosterone (FT)
In the present study, serum free testosterone in patients with ACS was
studied and compared with controls who had cardiovascular risk factors but no
evidence of CAD.
Of the 50 cases, 40 patients had serum free testosterone < 9 ng/dl which
was taken as significant based on other studies done. Among 25 controls, only 1
had serum free testosterone < 9 ng/dl and 24 had serum free testosterone > 9 ng/dl.
On applying chi-square test, the odd's ratio (95% CI) is 96 and risk ratio
(95% CI) is 3.32 and p value is highly significant (p<0.001). The means that
serum free testosterone was significantly decreased in patients who had ACS.
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The mean serum free testosterone in cases was 8.36±1.80 ng/dl and control
was 12.94±3.06 ng/dl. The difference was statistically significant (p value <
0.001).
In 2003 study, men with coronary artery disease had significantly lower
levels of free testosterone than did controls.
In 1994 study, it was found out that free testosterone correlated negatively
with the degree of coronary artery disease.
In 2007 study, it was found out that the patients had significantly lower
levels of testosterone than controls (9.8±6.5 mmol/l, p<0.01).
In 2000 study, it was concluded that men with coronary artery disease had
significantly lower level of free testosterone 47.95±13.77 pmol (p value = 0.027).
In 2009 study, it was found that total and free testosterone levels of the
patients with coronary artery disease were significantly lower than those of
controls.
In the present study, we found that the mean serum free testosterone in
patients with 0-2 cardiovascular risk factors was 8.02±1.23 ng/dl.
Mean serum free testosterone level in patients with > 3 cardiovascular risk
factors was 8.58±2.08 ng/dl.
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The difference between these 2 subgroups of ACS patients was not
statistically significant which means that the level of serum free testosterone level
decreases irrespective of the number of cardiovascular risk factors.
The inverse relationship between testosterone levels and coronary
atherosclerosis found in the present study suggests a possible protective role of the
hormone on the progression of atherosclerosis.
Serum free testosterone and hypertension
The mean serum free testosterone level in hypertensive cases was
8.38±1.56 ng/dl and hypertensive control was 11.5±1.85. The difference was
statistically significant.
In 2005 study, it was found that testosterone values were significantly
lower in hypertensive cases.
In 1994 study, it was demonstrated that testosterone is lower in populations
of men with hypertension than in normal men.
In 2007 study, a relationship between hypotestosteronemia and high blood
pressure was demonstrated.
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Serum free testosterone and smoking
The mean serum free testosterone in smokers with ACS was 8.72±1.96
ng/dl and serum free testosterone of smokers in control group was 11.1±2.21
ng/dl. The difference was statistically significant.
The 1990 study, 1993 study and 2000 study reported that smoking is a
strong risk factors for atherosclerosis.
Serum free testosterone and patterns of acute coronary syndrome
In the present study, most patients had AWMI (48%) and IWMI (32%).
Mean serum free testosterone was highest in AWMI (8.67±2.16 ng/dl) and lowest
in AWMI+IWMI (7.31±1.83 ng/dl).
Serum free testosterone and mortality in ACS
In the present study, most of the patients (96%) survived the illness while 2
patients died due to ACS.
The 2007 study concluded that testosterone concentrations are inversely
related to mortality due to cardiovascular disease.
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SUMMARY
? The present study included 50 patients who presented with acute coronary
syndrome and 25 patients of age matched controls without evidence of
CAD.
? In the study group, the mean age of presentation was 53.3 yrs.
? The commonest presenting symptom was chest pain followed by
palpitation.
? Hypertension present in 34% of cases and 28% of controls.
? Smoking incidence was 46% in cases and 20% in controls.
? Higher levels of total cholesterol, triglyceride and LDL cholesterol and
lower level of HDL cholesterol were seen in cases. They significantly differ
in comparison to controls.
? Of the cases studied, about 86% had STEMI and 14% had NSTEMI.
? The mean serum free testosterone was significantly lower in patients with
ACS.
? Serum free testosterone level was also significantly lower in patients with
hypertension and smokers.
? Mean serum free testosterone level did not relate to the number of
cardiovascular risk factors.
? Most of the patients (48%) presented with AWMI followed by IWMI
(32%).
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? Mean serum free testosterone level was lowest in patient who had
IWMI+AWMI as compared with other patterns of ACS.
? Of the 50 cases studied, 2 patients died (percentage of mortality - 4%).
? Mean serum free testosterone level was inversely related to hypertension,
dyslipidemia, smokers and BMI.
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CONCLUSION
? The serum free testosterone was found to be lower in patients with acute
coronary syndrome as compared to controls. The difference between cases
and controls was statistically significant.
? The serum free testosterone level was lowest in patients who presented with
AWMI+IWMI as compared with other patterns of ACS.
?  There was an inverse correlation found between serum free testosterone
level and mortality and morbidity in patients with acute coronary
syndrome.
? The serum free testosterone level was found to be lower in cases with
traditional risk factors like smoking, hypertension, dyslipidemia and BMI.
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FBS RBS
1 12621 Kandhasamy 35 Driver 12.10.12 19.10.12 Chest Pain
Palpitation  x 1 day
Smoker 104 80/60 18 175 67 21.83 NR Afebrile ST? in I,II, III aVL. aVF, V1-V6 5.2 84 145 +ve AWMI +
IWMI
TC 246, TG 147 HDL 30
LDL 126 VLDL -29
Urea 32
Creat.0.90
2 12732 Gurumoorthy 50 Shopkeeper 18.10.12 24.10.12 Chest Pain
Palpitation x 1 day
Smoker 76 110/70 18 170 75 25.95 NR Afebrile ST? in II, III  aVF, 8.4 90 103 +ve IWMI TC 246, TG 130 HDL 51
LDL 113 VLDL27
Urea -28
Creat. 0.81
3 12789 Sudhakaran 65 Driver 07.02.13 16.02.13 Chest pain
Palpitation x 4 hrs.
Tobacco Chewing 88 150/90 16 184 70 20.63 NR Afebrile ST? in precordial leads 7.1 92 130 +ve AWMI  TC 178, TG 194,HDL
46, LDL 120 VLDL 26
Urea - 30
Creat. 0.52
4 12801 Gopalakrishn
an
70 Driver 13.02.13 16.02.13 Chest Pain Nausea,
Vomiting, Abdominal
pain , Dizziness,
Palpitation x 4 days
Smoker 58 160/110 18 175 70 22.86 NR Afebrile ST? in V1 V2 V3 7 96 136 +ve AWMI TC 252, TG 148, HDL
39, LDL 130, VLDL 38
Urea - 14
Creat. 0.3
5 12815 Muthusamy 40 Shopkeeper 10.02.13 18.02.13 Chest pain x 4 hrs. Not Significant 74 160/110 24 180 74 22.79 NR Afebrile ST? in II, III aVF 6.8 78 102 +ve IWMI TC 260, TG 133, HDL
40, LDL 111, VLDL 33
Urea - 20
Creat-
6 12847 Mahendran 45 Worker 28.02.13 07.03.13 Chest pain,
uneasiness x 6 hrs.
Smoker 102 120/70 18 172 66 22.26 NR Afebrile ST? in aVL, V1 to V6 9 84 96 "+ve AWMI TC 210, TG 142, HDL
48, LDL 112, VLDL 42
Urea -30
7 12901 Arockiasamy 50 Shopkeeper 05.03.13 12.03.13 Chest pain,
Breathlessness,
Palpitation x 2 days
Chronic smoker 120 200/120 18 171 70 23.89 NR Afebrile ST? in V1 to  V3 14.3 76 110 +ve ASMI TC 265, TG 140, HDL
20, LDL 110, VLDL 24
Urea -25
Creat-0.6
8 12935 Krishnaraj 70 Businessman 28.03.13 02.04.13 Chestpain,
Palpitationx 1 day
Tobacco Chewing 88 140/90 16 165 68 24.92 NR Afebrile ST? in II, III aVF 7.9 74 92 +ve IWMI TC 270, TG 145, HDL
40, LDL 120, VLDL 42
Urea -26
Creat-0.4
9 12967 Ramgopal 50 Shopkeeper 28.03.13 02.04.13 Chestpain,
Palpitationx 1 day
Smoker 90 140/80 16 170 65 22.4 NR Afebrile ST? in II, III aVF 9.6 84 90 +ve IWMI TC 211, TG 130, HDL
54, LDL 126, VLDL 16
Urea -32
Creat-0.9
10 13112 Gopalsamy 50 Businessman 12.04.13 18.04.13 Chestpain x 5 hrs. Not Significant 120 130/80 16 172 60 20.24 NR Afebrile ST? in I, aVL   precordial leads 8.5 80 79 '+ve Ext.  AWMITC 173., TG 214, HDL
40, LDL 90, VLDL 42
Urea -48
Creat-0.9
11 13215 Hariharan 59 Fisherman 12.04.13 20.04.13 Chestpain x 1 day Not Significant 84 118/80 16 176 80 25.77 NR Afebrile ST? in I aVL V1 to V6 9.3 70 78 +ve NST EMI TC 290, TG 90, HDL 40,
LDL 111, VLDL 38
Urea -30
Creat-0.9
12 13298 Prakash 64 Coolie 13.04.13 21.04.13 Chestpain since 5
hrs
Not Significant 60 150/80 16 180 70 21.56 NR Afebrile ST? in II, III aVF 11.2 86 91 +ve IWMI TC 255, TG 145, HDL
30, LDL 125, VLDL 18
Urea -32
Creat-0.5
13 13356 Balamurugan 47 Businessman 12.04.13 18.04.13 Chestpain x 1 day Chronic smoker 88 140/100 16 177 70 22.29 NR Afebrile ST? in II, III aVF 8.45 95 107 +ve IWMI TC 167, TG 130, HDL
38, LDL 103, VLDL 26
Urea -33
Creat-0.7
14 13398 Ahamed 45 Driver 18.04.13 24.04.13 Chestpain x 8 days Chronic smoker 104 80/60 16 170 68 23.48 Raised Afebrile ST? in I, II, III aVF, aVL 8.45 78 108 +ve IWMI+
AWMI
TC 172, TG 130, HDL
47, LDL 136, VLDL 29
Urea -32
Creat-0.6
15 13421 Manoharan 45 Plumber 18.04.13 24.04.13 Chestpain x 4 hrs. Smoker 88 120/80 15 177 70 22.29 NR Afebrile ST? in II, III aVF & RsR' in v1 8.15 87 102 +ve IWMI+
RBB
TC 280, TG 139, HDL
43, LDL 112, VLDL 33
Urea -21
Creat-1
16 13498 Muthuraman 65 Electrician 06.04.13 11.04.13 Chestpain x 1 day Smoker 78 140/90 16 174 66 22.8 NR Afebrile ST? in II, III aVF 9.8 84 97 +ve IWMI TC 237, TG 137, HDL
52, LDL 114, VLDL 27
Urea -33
Creat-0.8
17 13526 Ashokan 43 Policeman 23.04.13 26.04.13 Chestpain x 1 day Not Significant 100 90/60 15 178 65 20.5 NR Afebrile Q wave in I & aVL, ST? inV5 V6 8.6 79 130 +ve ALMI TC 169, TG 80, HDL 48,
LDL 105, VLDL 16
Urea -46
Creat-1.59
18 13701 Moorthy 64 Plumber 17.04.13 23.04.13 Chestpain x 1 day Not Significant 86 120/80 18 173 80 26.67 NR Afebrile ST? in precordial leads 8.67 84 99 +ve AWMI TC 261, TG 147, HDL
35, LDL 126, VLDL 35
Urea -27
Creat-0.7
19 13820 Ramanujam 64 Coolie 15.04.13 Exp. Chestpain,
heaviness of chest,
dizziness,
Palpitation, vomiting
x 1day
Not Significant 74 110/80 16 168 70 24.8 NR Afebrile ST? in I,aVL V4 to V6 13.4 80 86 +ve ALMI TC 300, TG 160, HDL
30, LDL 140, VLDL 46
Urea -30
Creat-0.1
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20 13917 Krishnan 75 Driver 23.04.13 Exp. Breathlessness,
chest discomfort x 1
day
Not Significant 92 110/70 18 170 60 20.8 NR Afebrile ST? in precordial leads 6.8 72 90 +ve AWMI TC 200, TG 130, HDL
40, LDL 156, VLDL 44
Urea -12
Creat-0.4
21 14002 Muthukumar 64 Electrician 24.04.13 28.04.13 Chestpain,
palpitation x 1 day
Tobacco Chewing 100 130/80 16 174 74 25 NR Afebrile ST? in II,III aVF 8.6 86 120 '+ve IWMI TC 262, TG 151, HDL
51, LDL 146, VLDL 45
Urea -37
Creat-0.56
22 14119 Raman 45 Fisherman 02.05.13 10.05.13 Chestpain x 1 day Chronic smoker 90 150/90 16 180 70 21.6 NR Afebrile ST? in I aVL V1 to V6 7.2 74 103 +ve AWMI TC 210, TG 156, HDL
40, LDL 110, VLDL 42
Urea -45
Creat-0.81
23 14185 Govindhan 50 Plumber 02.05.13 09.05.13 Chestpain,
palpitation, vomiting
since 1 day
Not Significant 100 90/60 16 174 70 23.1 NR Afebrile ST? in II, III aVF 5.2 74 108 +ve IWMI TC 272, TG 171, HDL
50, LDL 148, VLDL 42
Urea -40
Creat-0.31
24 14325 Sundaram 40 Electrician 09.05.13 16.05.13 Chestpain,
Palpitation  x 2 hrs.
Smoker 80 120/70 16 178 70 22.1 NR Afebrile ST? in V1 to V6 8.2 81 90 +ve AWMI TC 300, TG 152, HDL
46, LDL 120, VLDL 42
Urea -36
Creat-0.4
25 14506 Suresh 58 Mill Worker 09.05.13 16.05.13 Chestpain x 1 day Tobacco Chewing 78 170/110 16 179 62 19.4 NR Afebrile ST? in V1 to V3 7.7 72 84 +ve ASMI TC 287, TG 151, HDL
26, LDL 150, VLDL 40
Urea -38
Creat-0.6
26 14611 Ramkumar 65 Coolie 13.05.13 21.05.13 Chestpain,
palpitation x 1 day
Not Significant 85 120/70 16 174 74 24.4 NR Afebrile ST? in I aVL II, III aVF, V1 to V6 8.3 76 98 +ve IWMI+
AWMI
TC 171, TG 151, HDL
38, LDL 102, VLDL 30
Urea -16
Creat-0.03
27 14678 Suresh 55 Mill Worker 16.05.13 24.05.13 Not Significant 136 160/80 18 171 70 23.9 NR Afebrile ST? in II, III aVF 8.2 74 90 +ve IWMI TC 270, TG 200, HDL
38, LDL 140, VLDL 42
Urea -32
Creat-0.4
28 14721 Manoharan 43 Plumber 21.05.13 29.05.13 Chestpain,
palpitation  x 1day
Not Significant 100 110/70 16 178 80 25.2 NR Afebrile  ST? in I aVL V1 to  V6 7.8 79 104 +ve AWMI TC 147, TG 95, HDL 32,
LDL 96, VLDL 19
Urea -32
Creat-1.01
29 14890 Sreeram 60 Driver 21.05.13 29.05.13 Chestpain,
palpitation  x 1 day
Smoker and
alcoholics
70 140/90 20 168 60 21.3 NR Afebrile ST? in precordial leads 8 86 99 +ve AWMI TC 200, TG 130, HDL
43, LDL 127, VLDL 18
Urea -37
Creat-0.5
30 15200 Ramasamy 65 Pensioner 22.05.13 29.05.13 Chestpain,
Palpitation,
Dizziness  x 1 day
Tobacco Chewing 90 130/90 16 172 72 24.3 NR Afebrile Normal ECG 8 85 106 +ve NST EMI TC 163, TG 75, HDL 47,
LDL 130, VLDL 13
Urea -30
Creat-0.7
31 15401 Dinesh 41 Driver 22.05.13 30.05.13 Chestpain,
palpitation  x 1 day
Not Significant 86 130/80 16 170 62 21.5 NR Afebrile ST? in V1, V2,V3 6.7 80 96 +ve ASMI TC 239, TG 154, HDL
45, LDL 163, VLDL 30
Urea -21
Creat-0.7
32 15721 Gurusamy 40 Mill Worker 30.05.13 06.06.13 Chestpain,
palpitation  x 1 day
Smoker 62 130/80 16 158 70 28 NR Afebrile ST? in precordial leads 8.5 81 102 +ve AWMI TC 268, TG 182, HDL
25, LDL 142, VLDL 52
Urea -24
Creat-0.6
33 15832 Faisal 63 Driver 07.06.13 14.06.13 Chestpain,
palpitation x 1 day
Not Significant 88 170/110 18 175 70 22.9 NR Afebrile ST? in precordial leads 8 82 130 '+ve AWMI TC 208, TG 92, HDL 42,
LDL 107, VLDL 18
Urea -19
Creat-0.1
34 16010 Azhagesan 40 Policeman 09.06.13 20.06.13 Chestpain,
palpitation, sweating
x 1 day
Not Significant 100 100/60 18 178 64 20.2 NR Afebrile ST? in I aVL V1 to V6 8.4 70 98 +ve AWMI TC 128, TG 62, HDL 30,
LDL 75, VLDL 12
Urea -32
Creat-0.7
35 16125 Muthuraman 62 Teacher 09.06.13 16.06.13 Chestpain,
palpitation, sweating,
vomiting since 1 day
Not Significant 90 130/90 14 170 67 23.2 NR Afebrile ST? in II, III aVF 8.8 90 102 +ve IWMI TC 126, TG 56, HDL 27,
LDL 87, VLDL 11
Urea -20
Creat-0.5
36 16303 Mohan 50 Teacher 13.6.13 19.06.13 Chestpain,
Palpitation  x ½ hrs.
Not Significant 100 120/80 16 168 76 26.9 NR Afebrile Normal ECG 5.9 99 102 +ve NST EMI TC 175, TG 129, HDL
30, LDL 119, VLDL 25
Urea -18
Creat-0.77
37 16534 Ashokan 42 Coolie 13.06.13 18.06.13 Chestpain x 1 day Smoking 80 130/80 14 169 78 27.3 NR Afebrile T? in I aVL V3 to V6 7.2 90 108 +ve NST EMI TC 178, TG 133, HDL
42, LDL 117, VLDL 43
Urea -21
Creat-0.2
38 16855 Krishnaraj 74 Farmer 13.06.13 17.06.13 Chestpain,
palpitation x 1 day
Not Significant 96 150/90 16 166 80 29 NR Afebrile ST? in II, III aVF 8.1 58 88 +ve IWMI TC 172, TG 148, HDL
52, LDL 90, VLDL 29
Urea -17
Creat-0.5
39 17290 Selvam 52 Coolie 20.06.06 26.06.13 Palpitation, sweating
x 1 day
Smoking 100 160/110 14 165 74 27.2 NR Afebrile Normal ECG 9.2 82 98 +ve NST EMI TC 268, TG 133, HDL
54, LDL 188, VLDL 26
Urea -16
Creat-0.3
FBS RBS
Occupation Presenting
complaints
S.No. I.P.No Name Age DOA DOD/
Death
ECG on
admission
Pulse
b.p.m.
B.P.
mmHg
R/R Hight
c.m.
General examination
BMI JVP Temp.
RFTDiagnosis
Serum free
testosteron
e level
(ng/dL)
Blood
Sugar
(mg%)
Tr
op
on
in
 T
Personal
History
Lipid
Profile
Investigations
Weight
kg
40 17475 Rajkumar 40 Govt. Servant 21.06.13 28.06.13 Chestpain,
palpitation  x 1day
Not Significant 90 170/110 18 176 70 22.6 NR Afebrile ST? in precordial leads 8.9 74 108 +ve AWMI TC 153, TG 142, HDL
27, LDL 97, VLDL 28
Urea -20
Creat-0.5
41 17633 Muthusamy 40 Shopkeeper 21.06.13 28.06.13 Chestpain, x 1 day Smoking 98 100/80 16 174 65 21.5 NR Afebrile ST? in I aVL V1 to V6 13.4 94 111 +ve AWMI TC 246, TG 118, HDL
41, LDL 181, VLDL 23
Urea -31
Creat-1
42 18011 Singaram 56 Coolie 21.06.13 30.06.13 Chestpain x 10 days Not Significant 94 100/70 18 176 70 22.6 NR Afebrile ST? in II, III aVF 8.2 76 94 +ve IWMI TC 225, TG 163, HDL
62, LDL 160, VLDL 32
Urea -22
Creat-0.7
43 18305 Ramesh 45 Govt. Servant 23.06.13 30.06.13 Chestpain x 1 day Smoking 76 140/80 16 170 56 19.4 NR Afebrile ST? in II, III aVF 8.6 82 113 +ve IWMI TC 252, TG 110, HDL
42, LDL 152, VLDL 13
Urea -22
Creat-0.6
44 18567 Kalimuthu 55 Farmer 26.06.13 04.07.13 Chestpain,
palpitation x 1 day
Smoking 90 110/70 18 160 70 27.3 NR Afebrile ST? in II, III aVF 10.2 80 95 +ve AWMI TC 181, TG 120, HDL
45, LDL 123, VLDL 20
Urea -40
Creat-0.8
45 18987 Krishan 55 Govt. Servant 26.06.13 02.07.13 Chest, Palpitation, x
1 day
Smoking 106 110/70 14 174 80 26.4 NR Afebrile ST? in precordial leads 8.6 72 79 +ve NST EMI TC 268, TG 133, HDL
54, LDL 188, VLDL 26
Urea -16
Creat-0.3
46 19017 Muralidharan 65 Mill Worker 27.06.13 02.07.13 Breathlessness,
palpitation  x 1 day
Not Significant 100 110/70 16 176 71 22.9 NR Afebrile ST? in precordial leads 5.6 66 96 +ve AWMI TC 270, TG 130, HDL
42, LDL 100, VLDL 27
Urea -16
Creat-0.72
47 19219 Shanmugam 40 Govt. Servant 07.07.13 16.07.13 Breathlessness,
palpitation  x 1 day
Smoking 76 130/80 16 180 68 21 NR Afebrile ST? in V2  V3 8.8 70 84 +ve ASMI TC 118, TG 63, HDL 19,
LDL 85, VLDL 12
Urea -28
Creat-0.79
48 19325 Ramesh 56 Shopkeeper 09.07.13 16.07.13 Chestpain x 15 days Smoking 70 130/80 16 169 73 25.6 NR Afebrile ST? in I aVL, V2, -V6 7.3 76 85 +ve NST EMI TC 191, TG 215, HDL
46, LDL 101, VLDL 43
Urea -18
Creat-0.74
49 19567 Sulthan 61 Plumber 01.12.13 08.12.13 Chestpain x 1 day Not Significant 80 140/80 16 166 60 21.8 NR Afebrile ST? in II, III aVF 6.4 84 98 +ve IWMI TC 270, TG 164, HDL
20, LDL 157, VLDL 36
Urea -21
Creat-0.24
50 19702 Rajan 50 Mill Worker 01.12.13 07.12.13 Chestpain x 10 days Not Significant 84 120/70 16 174 72 23.8 NR Afebrile ST? in I, avL, V1-V6 7.4 84 95 +ve AWMI TC 210, TG 155, HDL
50, LDL 120, VLDL 32
Urea -25
Creat-0.94
FBS RBS
1 12621 Kandhasamy 35 Driver 12.10.12 19.10.12 Chest Pain
Palpitation  x 1 day
Smoker 104 80/60 18 175 67 21.83 NR Afebrile ST? in I,II, III aVL. aVF, V1-V6 5.2 84 145 +ve AWMI +
IWMI
TC 246, TG 147 HDL 30
LDL 126 VLDL -29
Urea 32
Creat.0.90
2 12732 Gurumoorthy 50 Shopkeeper 18.10.12 24.10.12 Chest Pain
Palpitation x 1 day
Smoker 76 110/70 18 170 75 25.95 NR Afebrile ST? in II, III  aVF, 8.4 90 103 +ve IWMI TC 246, TG 130 HDL 51
LDL 113 VLDL27
Urea -28
Creat. 0.81
3 12789 Sudhakaran 65 Driver 07.02.13 16.02.13 Chest pain
Palpitation x 4 hrs.
Tobacco Chewing 88 150/90 16 184 70 20.63 NR Afebrile ST? in precordial leads 7.1 92 130 +ve AWMI TC 178, TG 194,HDL 46,
LDL 120 VLDL 26
Urea - 30
Creat. 0.52
4 12801 Gopalakrishn
an
70 Driver 13.02.13 16.02.13 Chest Pain Nausea,
Vomiting, Abdominal
pain , Dizziness,
Palpitation x 4 days
Smoker 58 160/110 18 175 70 22.86 NR Afebrile ST? in V1 V2 V3 7 96 136 +ve AWMI TC 252, TG 148, HDL
39, LDL 130, VLDL 38
Urea - 14
Creat. 0.3
5 12815 Muthusamy 40 Shopkeeper 10.02.13 18.02.13 Chest pain x 4 hrs. Not Significant 74 160/110 24 180 74 22.79 NR Afebrile ST? in II, III aVF 6.8 78 102 +ve IWMI TC 260, TG 133, HDL
40, LDL 111, VLDL 33
Urea - 20
Creat-
6 12847 Mahendran 45 Worker 28.02.13 07.03.13 Chest pain,
uneasiness x 6 hrs.
Smoker 102 120/70 18 172 66 22.26 NR Afebrile ST? in aVL, V1 to V6 9 84 96 "+ve AWMI TC 210, TG 142, HDL
48, LDL 112, VLDL 42
Urea -30
7 12901 Arockiasamy 50 Shopkeeper 05.03.13 12.03.13 Chest pain,
Breathlessness,
Palpitation x 2 days
Chronic smoker 120 200/120 18 171 70 23.89 NR Afebrile ST? in V1 to  V3 14.3 76 110 +ve ASMI TC 265, TG 140, HDL
20, LDL 110, VLDL 24
Urea -25
Creat-0.6
8 12935 Krishnaraj 70 Businessman 28.03.13 02.04.13 Chestpain,
Palpitationx 1 day
Tobacco Chewing 88 140/90 16 165 68 24.92 NR Afebrile ST? in II, III aVF 7.9 74 92 +ve IWMI TC 270, TG 145, HDL
40, LDL 120, VLDL 42
Urea -26
Creat-0.4
9 12967 Ramgopal 50 Shopkeeper 28.03.13 02.04.13 Chestpain,
Palpitationx 1 day
Smoker 90 140/80 16 170 65 22.4 NR Afebrile ST? in II, III aVF 9.6 84 90 +ve IWMI TC 211, TG 130, HDL
54, LDL 126, VLDL 16
Urea -32
Creat-0.9
10 13112 Gopalsamy 50 Businessman 12.04.13 18.04.13 Chestpain x 5 hrs. Not Significant 120 130/80 16 172 60 20.24 NR Afebrile ST? in I, aVL   precordial leads 8.5 80 79 '+ve Ext.  AWMI TC 173., TG 214, HDL
40, LDL 90, VLDL 42
Urea -48
Creat-0.9
11 13215 Hariharan 59 Fisherman 12.04.13 20.04.13 Chestpain x 1 day Not Significant 84 118/80 16 176 80 25.77 NR Afebrile ST? in I aVL V1 to V6 9.3 70 78 +ve NST EMI TC 290, TG 90, HDL 40,
LDL 111, VLDL 38
Urea -30
Creat-0.9
12 13298 Prakash 64 Coolie 13.04.13 21.04.13 Chestpain since 5 hrs Not Significant 60 150/80 16 180 70 21.56 NR Afebrile ST? in II, III aVF 11.2 86 91 +ve IWMI TC 255, TG 145, HDL
30, LDL 125, VLDL 18
Urea -32
Creat-0.5
13 13356 Balamurugan 47 Businessman 12.04.13 18.04.13 Chestpain x 1 day Chronic smoker 88 140/100 16 177 70 22.29 NR Afebrile ST? in II, III aVF 8.45 95 107 +ve IWMI TC 167, TG 130, HDL
38, LDL 103, VLDL 26
Urea -33
Creat-0.7
14 13398 Ahamed 45 Driver 18.04.13 24.04.13 Chestpain x 8 days Chronic smoker 104 80/60 16 170 68 23.48 Raised Afebrile ST? in I, II, III aVF, aVL 8.45 78 108 +ve IWMI+
AWMI
TC 172, TG 130, HDL
47, LDL 136, VLDL 29
Urea -32
Creat-0.6
15 13421 Manoharan 45 Plumber 18.04.13 24.04.13 Chestpain x 4 hrs. Smoker 88 120/80 15 177 70 22.29 NR Afebrile ST? in II, III aVF & RsR' in v1 8.15 87 102 +ve IWMI+
RBB
TC 280, TG 139, HDL
43, LDL 112, VLDL 33
Urea -21
Creat-1
16 13498 Muthuraman 65 Electrician 06.04.13 11.04.13 Chestpain x 1 day Smoker 78 140/90 16 174 66 22.8 NR Afebrile ST? in II, III aVF 9.8 84 97 +ve IWMI TC 237, TG 137, HDL
52, LDL 114, VLDL 27
Urea -33
Creat-0.8
17 13526 Ashokan 43 Policeman 23.04.13 26.04.13 Chestpain x 1 day Not Significant 100 90/60 15 178 65 20.5 NR Afebrile Q wave in I & aVL, ST? inV5 V6 8.6 79 130 +ve ALMI TC 169, TG 80, HDL 48,
LDL 105, VLDL 16
Urea -46
Creat-1.59
18 13701 Moorthy 64 Plumber 17.04.13 23.04.13 Chestpain x 1 day Not Significant 86 120/80 18 173 80 26.67 NR Afebrile ST? in precordial leads 8.67 84 99 +ve AWMI TC 261, TG 147, HDL
35, LDL 126, VLDL 35
Urea -27
Creat-0.7
19 13820 Ramanujam 64 Coolie 15.04.13 Exp. Chestpain, heaviness
of chest, dizziness,
Palpitation, vomiting x
1day
Not Significant 74 110/80 16 168 70 24.8 NR Afebrile ST? in I,aVL V4 to V6 13.4 80 86 +ve ALMI TC 300, TG 160, HDL
30, LDL 140, VLDL 46
Urea -30
Creat-0.1
20 13917 Krishnan 75 Driver 23.04.13 Exp. Breathlessness,
chest discomfort x 1
day
Not Significant 92 110/70 18 170 60 20.8 NR Afebrile ST? in precordial leads 6.8 72 90 +ve AWMI TC 200, TG 130, HDL
40, LDL 156, VLDL 44
Urea -12
Creat-0.4
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21 14002 Muthukumar 64 Electrician 24.04.13 28.04.13 Chestpain, palpitation
x 1 day
Tobacco Chewing 100 130/80 16 174 74 25 NR Afebrile ST? in II,III aVF 8.6 86 120 '+ve IWMI TC 262, TG 151, HDL
51, LDL 146, VLDL 45
Urea -37
Creat-0.56
22 14119 Raman 45 Fisherman 02.05.13 10.05.13 Chestpain x 1 day Chronic smoker 90 150/90 16 180 70 21.6 NR Afebrile ST? in I aVL V1 to V6 7.2 74 103 +ve AWMI TC 210, TG 156, HDL
40, LDL 110, VLDL 42
Urea -45
Creat-0.81
23 14185 Govindhan 50 Plumber 02.05.13 09.05.13 Chestpain, palpitation,
vomiting since 1 day
Not Significant 100 90/60 16 174 70 23.1 NR Afebrile ST? in II, III aVF 5.2 74 108 +ve IWMI TC 272, TG 171, HDL
50, LDL 148, VLDL 42
Urea -40
Creat-0.31
24 14325 Sundaram 40 Electrician 09.05.13 16.05.13 Chestpain, Palpitation
x 2 hrs.
Smoker 80 120/70 16 178 70 22.1 NR Afebrile ST? in V1 to V6 8.2 81 90 +ve AWMI TC 300, TG 152, HDL
46, LDL 120, VLDL 42
Urea -36
Creat-0.4
25 14506 Suresh 58 Mill Worker 09.05.13 16.05.13 Chestpain x 1 day Tobacco Chewing 78 170/110 16 179 62 19.4 NR Afebrile ST? in V1 to V3 7.7 72 84 +ve ASMI TC 287, TG 151, HDL
26, LDL 150, VLDL 40
Urea -38
Creat-0.6
26 14611 Ramkumar 65 Coolie 13.05.13 21.05.13 Chestpain, palpitation
x 1 day
Not Significant 85 120/70 16 174 74 24.4 NR Afebrile ST? in I aVL II, III aVF, V1 to V6 8.3 76 98 +ve IWMI+
AWMI
TC 171, TG 151, HDL
38, LDL 102, VLDL 30
Urea -16
Creat-0.03
27 14678 Suresh 55 Mill Worker 16.05.13 24.05.13 Not Significant 136 160/80 18 171 70 23.9 NR Afebrile ST? in II, III aVF 8.2 74 90 +ve IWMI TC 270, TG 200, HDL
38, LDL 140, VLDL 42
Urea -32
Creat-0.4
28 14721 Manoharan 43 Plumber 21.05.13 29.05.13 Chestpain, palpitation
x 1day
Not Significant 100 110/70 16 178 80 25.2 NR Afebrile  ST? in I aVL V1 to  V6 7.8 79 104 +ve AWMI TC 147, TG 95, HDL 32,
LDL 96, VLDL 19
Urea -32
Creat-1.01
29 14890 Sreeram 60 Driver 21.05.13 29.05.13 Chestpain, palpitation
x 1 day
Smoker and
alcoholics
70 140/90 20 168 60 21.3 NR Afebrile ST? in precordial leads 8 86 99 +ve AWMI TC 200, TG 130, HDL
43, LDL 127, VLDL 18
Urea -37
Creat-0.5
30 15200 Ramasamy 65 Pensioner 22.05.13 29.05.13 Chestpain,
Palpitation, Dizziness
x 1 day
Tobacco Chewing 90 130/90 16 172 72 24.3 NR Afebrile Normal ECG 8 85 106 +ve NST EMI TC 163, TG 75, HDL 47,
LDL 130, VLDL 13
Urea -30
Creat-0.7
31 15401 Dinesh 41 Driver 22.05.13 30.05.13 Chestpain, palpitation
x 1 day
Not Significant 86 130/80 16 170 62 21.5 NR Afebrile ST? in V1, V2,V3 6.7 80 96 +ve ASMI TC 239, TG 154, HDL
45, LDL 163, VLDL 30
Urea -21
Creat-0.7
32 15721 Gurusamy 40 Mill Worker 30.05.13 06.06.13 Chestpain, palpitation
x 1 day
Smoker 62 130/80 16 158 70 28 NR Afebrile ST? in precordial leads 8.5 81 102 +ve AWMI TC 268, TG 182, HDL
25, LDL 142, VLDL 52
Urea -24
Creat-0.6
33 15832 Faisal 63 Driver 07.06.13 14.06.13 Chestpain, palpitation
x 1 day
Not Significant 88 170/110 18 175 70 22.9 NR Afebrile ST? in precordial leads 8 82 130 '+ve AWMI TC 208, TG 92, HDL 42,
LDL 107, VLDL 18
Urea -19
Creat-0.1
34 16010 Azhagesan 40 Policeman 09.06.13 20.06.13 Chestpain, palpitation,
sweating  x 1 day
Not Significant 100 100/60 18 178 64 20.2 NR Afebrile ST? in I aVL V1 to V6 8.4 70 98 +ve AWMI TC 128, TG 62, HDL 30,
LDL 75, VLDL 12
Urea -32
Creat-0.7
35 16125 Muthuraman 62 Teacher 09.06.13 16.06.13 Chestpain, palpitation,
sweating, vomiting
since 1 day
Not Significant 90 130/90 14 170 67 23.2 NR Afebrile ST? in II, III aVF 8.8 90 102 +ve IWMI TC 126, TG 56, HDL 27,
LDL 87, VLDL 11
Urea -20
Creat-0.5
36 16303 Mohan 50 Teacher 13.6.13 19.06.13 Chestpain, Palpitation
x ½ hrs.
Not Significant 100 120/80 16 168 76 26.9 NR Afebrile Normal ECG 5.9 99 102 +ve NST EMI TC 175, TG 129, HDL
30, LDL 119, VLDL 25
Urea -18
Creat-0.77
37 16534 Ashokan 42 Coolie 13.06.13 18.06.13 Chestpain x 1 day Smoking 80 130/80 14 169 78 27.3 NR Afebrile T? in I aVL V3 to V6 7.2 90 108 +ve NST EMI TC 178, TG 133, HDL
42, LDL 117, VLDL 43
Urea -21
Creat-0.2
38 16855 Krishnaraj 74 Farmer 13.06.13 17.06.13 Chestpain, palpitation
x 1 day
Not Significant 96 150/90 16 166 80 29 NR Afebrile ST? in II, III aVF 8.1 58 88 +ve IWMI TC 172, TG 148, HDL
52, LDL 90, VLDL 29
Urea -17
Creat-0.5
39 17290 Selvam 52 Coolie 20.06.06 26.06.13 Palpitation, sweating
x 1 day
Smoking 100 160/110 14 165 74 27.2 NR Afebrile Normal ECG 9.2 82 98 +ve NST EMI TC 268, TG 133, HDL
54, LDL 188, VLDL 26
Urea -16
Creat-0.3
40 17475 Rajkumar 40 Govt. Servant 21.06.13 28.06.13 Chestpain, palpitation
x 1day
Not Significant 90 170/110 18 176 70 22.6 NR Afebrile ST? in precordial leads 8.9 74 108 +ve AWMI TC 153, TG 142, HDL
27, LDL 97, VLDL 28
Urea -20
Creat-0.5
41 17633 Muthusamy 40 Shopkeeper 21.06.13 28.06.13 Chestpain, x 1 day Smoking 98 100/80 16 174 65 21.5 NR Afebrile ST? in I aVL V1 to V6 13.4 94 111 +ve AWMI TC 246, TG 118, HDL
41, LDL 181, VLDL 23
Urea -31
Creat-1
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42 18011 Singaram 56 Coolie 21.06.13 30.06.13 Chestpain x 10 days Not Significant 94 100/70 18 176 70 22.6 NR Afebrile ST? in II, III aVF 8.2 76 94 +ve IWMI TC 225, TG 163, HDL
62, LDL 160, VLDL 32
Urea -22
Creat-0.7
43 18305 Ramesh 45 Govt. Servant 23.06.13 30.06.13 Chestpain x 1 day Smoking 76 140/80 16 170 56 19.4 NR Afebrile ST? in II, III aVF 8.6 82 113 +ve IWMI TC 252, TG 110, HDL
42, LDL 152, VLDL 13
Urea -22
Creat-0.6
44 18567 Kalimuthu 55 Farmer 26.06.13 04.07.13 Chestpain, palpitation
x 1 day
Smoking 90 110/70 18 160 70 27.3 NR Afebrile ST? in II, III aVF 10.2 80 95 +ve AWMI TC 181, TG 120, HDL
45, LDL 123, VLDL 20
Urea -40
Creat-0.8
45 18987 Krishan 55 Govt. Servant 26.06.13 02.07.13 Chest, Palpitation, x 1
day
Smoking 106 110/70 14 174 80 26.4 NR Afebrile ST? in precordial leads 8.6 72 79 +ve NST EMI TC 268, TG 133, HDL
54, LDL 188, VLDL 26
Urea -16
Creat-0.3
46 19017 Muralidharan 65 Mill Worker 27.06.13 02.07.13 Breathlessness,
palpitation  x 1 day
Not Significant 100 110/70 16 176 71 22.9 NR Afebrile ST? in precordial leads 5.6 66 96 +ve AWMI TC 270, TG 130, HDL
42, LDL 100, VLDL 27
Urea -16
Creat-0.72
47 19219 Shanmugam 40 Govt. Servant 07.07.13 16.07.13 Breathlessness,
palpitation  x 1 day
Smoking 76 130/80 16 180 68 21 NR Afebrile ST? in V2  V3 8.8 70 84 +ve ASMI TC 118, TG 63, HDL 19,
LDL 85, VLDL 12
Urea -28
Creat-0.79
48 19325 Ramesh 56 Shopkeeper 09.07.13 16.07.13 Chestpain x 15 days Smoking 70 130/80 16 169 73 25.6 NR Afebrile ST? in I aVL, V2, -V6 7.3 76 85 +ve NST EMI TC 191, TG 215, HDL
46, LDL 101, VLDL 43
Urea -18
Creat-0.74
49 19567 Sulthan 61 Plumber 01.12.13 08.12.13 Chestpain x 1 day Not Significant 80 140/80 16 166 60 21.8 NR Afebrile ST? in II, III aVF 6.4 84 98 +ve IWMI TC 270, TG 164, HDL
20, LDL 157, VLDL 36
Urea -21
Creat-0.24
50 19702 Rajan 50 Mill Worker 01.12.13 07.12.13 Chestpain x 10 days Not Significant 84 120/70 16 174 72 23.8 NR Afebrile ST? in I, avL, V1-V6 7.4 84 95 +ve AWMI TC 210, TG 155, HDL
50, LDL 120, VLDL 32
Urea -25
Creat-0.94
